C-Path's Disease Modeling Coalition Begins Global Pediatric IBD Work from European Hub

EQS-News: Critical Path Institute / Key word(s): Product Launch C-Path's Disease Modeling Coalition Begins Global Pediatric IBD Work from European Hub 16.10.2025 / 10:10 CET/CEST The issuer is solely responsible for the content of this announcement. AMSTERDAM, Oct. 16, 2025 /PRNewswire/ -- Critical Path Institute (C-Path) today announced the official launch of the Critical Path Disease Modeling Coalition (CP-DMC) on pediatric inflammatory bowel disease (pIBD). This is a multi-stakeholder, public-private initiative to develop regulatory-grade, quantitative disease progression and care models to accelerate and better inform drug development and evaluations for pediatric Crohn's disease and ulcerative colitis.

Launched with leading academics and clinicians from the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN), including Prof. Lissy de Ridder, M.D., Ph.D., Head of Department of Pediatrics, Leiden University Medical Center, based in Geneva, and supported by the Crohn's & Colitis Foundation, based in New York, the project brings together expertise and capabilities in medical practice, clinical and real-world data science, and regulatory science to build fit-for-purpose reference simulation models usable across programs and sponsors.

CP-DMC is being established with Quinten Health as the founding AI and disease modeling partner, working alongside both C-Path's Quantitative Medicine Program and Data Collaboration Center to integrate clinical trial and real-world data at scale for model development and application.

"The launch of the CP-DMC Pediatric IBD Project represents a pivotal step in how we develop medicines for children with chronic inflammatory diseases," said Cécile Ollivier, C-Path Vice President of Global Affairs and CP-DMC Lead. "Through this pre-competitive collaboration that unites regulators, clinicians, industry, and people living with the condition in a globally aligned framework, we can deliver tools that reflect real disease complexity and speed up innovation where it is most needed."